What is Zacks Research's Estimate for Amarin Q3 Earnings?

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research increased their Q3 2025 EPS estimates for shares of Amarin in a research note issued on Wednesday, June 25th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.60) per share for the quarter, up from their previous estimate of ($0.74). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.59) EPS, Q1 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.67) EPS.

AMRN has been the topic of several other research reports. The Goldman Sachs Group increased their target price on Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a research note on Wednesday. Wall Street Zen raised shares of Amarin from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th.

Amarin Trading Down 1.8%

Shares of NASDAQ AMRN opened at $15.90 on Friday. Amarin has a twelve month low of $7.08 and a twelve month high of $17.18. The stock has a fifty day simple moving average of $11.66 and a 200-day simple moving average of $10.64. The stock has a market capitalization of $329.29 million, a PE ratio of -4.37 and a beta of 0.71.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative return on equity of 17.21%.

Hedge Funds Weigh In On Amarin

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new stake in shares of Amarin in the first quarter valued at $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Amarin during the 4th quarter worth $36,000. Kornitzer Capital Management Inc. KS increased its holdings in Amarin by 4.0% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 3,400 shares during the period. Generation Capital Management LLC purchased a new stake in Amarin during the 4th quarter worth about $50,000. Finally, Stonepine Capital Management LLC acquired a new stake in Amarin in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.